Published in Radiol Med on June 19, 2015
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Renal-cell carcinoma. N Engl J Med (1996) 11.46
The changing natural history of renal cell carcinoma. J Urol (2001) 4.72
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology (2006) 2.59
Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology (2012) 2.35
Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology (2007) 2.16
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology (2009) 2.08
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology (2009) 1.94
Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology (2005) 1.76
Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging. Radiology (2004) 1.61
Angiomyolipoma: imaging findings in lesions with minimal fat. Radiology (1997) 1.44
Characterizing solid renal neoplasms with MRI in adults. Abdom Imaging (2014) 1.39
Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology (2010) 1.26
Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients. Urology (2008) 1.24
Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine. Int J Cardiovasc Imaging (2011) 1.17
Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol (1999) 1.17
The role of the ADC value in the characterisation of renal carcinoma by diffusion-weighted MRI. Br J Radiol (2009) 1.15
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol (2010) 1.14
Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology (2001) 1.13
Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol (1997) 1.09
Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT? AJR Am J Roentgenol (2011) 1.07
T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology (2009) 1.05
Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol (1998) 1.05
MR imaging of renal masses interpreted on CT to be suspicious. AJR Am J Roentgenol (2000) 1.05
T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol (2015) 1.02
Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol (2003) 1.01
Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis. Tumour Biol (2014) 0.99
Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol (2011) 0.99
Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? J Clin Pathol (2013) 0.99
Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol (2004) 0.96
Role of diffusion-weighted magnetic resonance imaging in characterization of renal tumors. J Comput Assist Tomogr (2011) 0.96
Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol (2006) 0.96
Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol (2014) 0.95
Application of ADC measurement in characterization of renal cell carcinomas with different pathological types and grades by 3.0T diffusion-weighted MRI. Eur J Radiol (2012) 0.94
Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol (2003) 0.93
Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology (2004) 0.92
Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol (2006) 0.91
Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology (2005) 0.91
Subtypes of renal cell carcinoma: MRI and pathological features. Diagn Interv Radiol (2013) 0.90
Liver directed therapy for renal cell carcinoma. J Cancer (2012) 0.90
Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. Eur J Cancer (2013) 0.89
Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. Eur J Radiol (2014) 0.89
Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol (2000) 0.88
Incidence and risk factors of chronic kidney disease in korean patients with t1a renal cell carcinoma before and after radical or partial nephrectomy. Jpn J Clin Oncol (2013) 0.88
Renal function following curative surgery for renal cell carcinoma: who is at risk for renal insufficiency? Korean J Urol (2013) 0.83
Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Rofo (2014) 0.83
Various radiological appearances of angiomyolipomas in the same kidney. Eur Radiol (2000) 0.83
Utility of apparent diffusion coefficients in the evaluation of solid renal tumors at 3T. Magn Reson Med Sci (2014) 0.81
Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. AJR Am J Roentgenol (2015) 0.81
Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine. AJR Am J Roentgenol (2008) 0.81
Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Radiology (2015) 0.81
Risk factors for acute kidney injury after radical nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma. J Vasc Surg (2013) 0.81
Magnetic resonance imaging in the detection and characterization of renal diseases. Saudi J Kidney Dis Transpl (2008) 0.80
Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol (2009) 0.80
Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study). J Magn Reson Imaging (2013) 0.79
MDCT-based scoring system for differentiating angiomyolipoma with minimal fat from renal cell carcinoma. Acta Radiol (2013) 0.79
Chronic renal insufficiency after partial nephrectomy for T1b tumors. Curr Opin Urol (2013) 0.79
Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial). Radiology (2010) 0.79
Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine. J Gastrointest Cancer (2010) 0.78
Comparison of 16-MDCT and MRI for characterization of kidney lesions. AJR Am J Roentgenol (2006) 0.78
Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio. Radiol Med (2003) 0.77
Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study). AJNR Am J Neuroradiol (2012) 0.77
Evaluation of renal masses with contrast-enhanced ultrasound. Curr Urol Rep (2013) 0.76
[Ultrasound and color Doppler imaging for kidney and urinary tract tumors]. G Ital Nefrol (2012) 0.76
Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions. J Comput Assist Tomogr (2012) 0.76
Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI. Eur J Radiol (2014) 0.76
Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. J Magn Reson Imaging (2014) 0.76
Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer. J Magn Reson Imaging (2014) 0.76